AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 151 min read$CSTL

MAETZOLD DEREK J sold $275K of CSTL

MAETZOLD DEREK J (Pres. & Chief Exec. Officer) sold 8,584 shares of CASTLE BIOSCIENCES INC (CSTL) at an average of $32.02 ($32.00–$32.78, $0.27M total) across 2 trades on 2026-09-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · MAETZOLD DEREK J
Published Sep 15, 2026, 8:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 8:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CSTL
Neutral
high confidence
Mentioned
$CSTL
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CSTLNeutralLow
01

Why it matters

The disclosed sale is modest and pre‑arranged, suggesting limited immediate market impact.

02

Market read

Minor insider sell‑off; unlikely to affect stock direction in the short term.

03

What to watch

Potential upcoming clinical data releases could affect insider behavior.

Relevance 3/10Novelty 4/10Timing: filed Sep 15, sale executed Sep 11

Background

Form 4 filing discloses insider transactions required by SEC; provides transparency on executive holdings.

Company-level read

Ticker impact

$CSTLNeutralHigh confidence
Context

CEO Derek Maetzold sold 8,584 shares for $274,862 via a 10b5‑1 plan, reducing his stake to 21,479 shares.

Expected impact

No significant impact; price may stay flat.

Evidence & confidence

The sale amount is small relative to market cap and follows a pre‑arranged plan, indicating no urgent information.

Market effects

Sector

No broader sector impact; insider sale is company‑specific.

Regional

None

Global

None

Counterpoint

What could challenge this read

Even small insider sales can signal confidence issues; monitor for further disposals.

Key entities

  • Executive
    Derek J. Maetzold

    President & Chief Executive Officer of Castle Biosciences

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CSTL insider trading history →

Related articles

SEP 28
$CSTLMedAI 8/10

Castle Biosciences Reports TissueCypher Changed Management In 90% Of NDBE Patients

Castle Biosciences (CSTL) published a study showing its TissueCypher test changed management in 90% of NDBE patients. The test, using AI-derived spatialomics, classified 17% as high risk, leading to escalated management, and 83% as low risk, leading to de-escalated management. The study involved 30 patients at Keck Medical Center of USC and was published in Foregut.

rttnews.com2 min
AUG 8
$CSTLMedAI 8/10

Castle Biosciences (CSTL) Q2 2026 Earnings Call Transcript

Castle Biosciences (CSTL) reported Q2 2026 total revenue of $103.5 million, up 20.1% from $86.2 million a year earlier, driven by TissueCypher volume and ASP gains. Management raised 2026 revenue guidance to $365 million to $375 million. Adjusted gross margin was 76.3% and adjusted EBITDA $12.4 million. Cash was $266.8 million at June 30, 2026.

fool.com6 min
JUL 30
$CSTLHigh

CASTLE BIOSCIENCES INC (CSTL): Results of Operations and Financial Condition

CASTLE BIOSCIENCES INC (CSTL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Castle Biosciences Reports Second Quarter 2026 Results Delivered Q2 2026 revenue of $103.5 million Q2 2026 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, TissueCypher ® ) increased 32% over Q2 2025 Raising full-year 2026 revenue guidance to

SEC EDGAR 8-K6 min